Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HARMONY BIOSCIENCES HOLDINGS, INC.

(HRMY)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 01/24 12:44:38 pm
33.085 USD   -1.94%
01/10INSIDER SELL : Harmony Biosciences Holdings
MT
01/07INSIDER SELL : Harmony Biosciences Holdings
MT
01/05Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HARMONY BIOSCIENCES : APPOINTS LINDA SZYPER TO ITS BOARD OF DIRECTORS - Form 8-K

11/22/2021 | 04:37pm EST

HARMONY BIOSCIENCES APPOINTS LINDA SZYPER TO ITS BOARD OF DIRECTORS

PLYMOUTH MEETING, PA, November 22, 2021 - Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Linda Szyper to the Company's Board of Directors.

Ms. Szyper brings extensive healthcare and pharmaceutical knowledge with expertise anchored in more than 30 years of experience that spans both pharmaceutical sales and marketing as well as healthcare communications services. Most recently, Ms. Szyper served as the Chief Operating Officer of McCann Health, a global healthcare communications company, where she was responsible for the development and overall operations of the global healthcare network. On Harmony's Board of Directors, she will serve as a member of the Nominating and Corporate Governance Committees.

"As Harmony aims to bring new treatment options to people living with rare diseases, I look forward to contributing my insights and experience in support of the company's talented team who are working to advance its mission on behalf of patients everywhere," said Ms. Szyper. "I am honored to join Harmony's Board at such a pivotal time of growth for the company and look forward to the opportunity ahead."

Prior to joining McCann Health, Ms. Szyper served as Chief Commercial Officer of Circassia, a publicly traded biotechnology and medical device company headquartered in the United Kingdom, from October 2014 to March 2017. In this role she spearheaded business strategy and commercial direction for the organization. Prior to Circassia Pharmaceuticals, she was the Chief Development Officer of Publicis Healthcare Communications Group, a healthcare communications network, from July 1999 to October 2014.

"Linda's operations and commercialization expertise are an asset to the Board," said Harmony Founder and Chairman, Jeff Aronin, Founder, Chairman and CEO of Paragon

Biosciences. "As Harmony continues to grow, her skills are important in our quest to help people living with unmet medical needs."

Ms. Szyper has also held roles of varying scopes and responsibilities at other life sciences and pharmaceutical companies, including Searle, a life sciences company where she oversaw global commercialization of its cardiovascular portfolio and its sleep therapeutic area; and Serono Laboratories, a biotechnology company where she managed sales and marketing for its reproductive and women's health business unit.

She received her Bachelor of Science in Biomedical Engineering from Northwestern University and earned her Master of Business Administration from DePaul University. She is based in Chicago.

About Harmony Biosciences
Harmony Biosciences is a commercial stage pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, and is focused on providing novel treatment options for people living with rare neurological diseases who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.

Harmony Biosciences Media Contact:
Nancy Leone
215-891-6046
nleone@harmonybiosciences.com

Harmony Biosciences Investor Contact:
Patti Bank
ICR Westwicke
415-513-1284
ir@harmonybiosciences.com

Disclaimer

Harmony Biosciences Holdings Inc. published this content on 22 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 November 2021 21:36:12 UTC.


ę Publicnow 2021
All news about HARMONY BIOSCIENCES HOLDINGS, INC.
01/10INSIDER SELL : Harmony Biosciences Holdings
MT
01/07INSIDER SELL : Harmony Biosciences Holdings
MT
01/05Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference
PR
2021HARMONY BIOSCIENCES HOLDINGS, INC.(N : HRMY) added to S&P Pharmaceuticals Select Industry ..
CI
2021HARMONY BIOSCIENCES HOLDINGS, INC.(N : HRMY) added to NASDAQ Biotechnology Index
CI
2021Harmony Biosciences to be Included in Nasdaq Biotechnology Index
MT
2021Harmony Biosciences to be Added to the Nasdaq Biotech Index
PR
2021Harmony Biosciences Publishes Pitolisant Efficacy Data In CNS Drugs
PR
2021Harmony Biosciences Holdings, Inc. Publishes Pitolisant Efficacy Data In CNS Drugs
CI
2021INSIDER SELL : Harmony Biosciences Holdings
MT
More news
Analyst Recommendations on HARMONY BIOSCIENCES HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 306 M - -
Net income 2021 38,5 M - -
Net cash 2021 12,0 M - -
P/E ratio 2021 51,7x
Yield 2021 -
Capitalization 1 973 M 1 973 M -
EV / Sales 2021 6,42x
EV / Sales 2022 3,85x
Nbr of Employees 150
Free-Float -
Chart HARMONY BIOSCIENCES HOLDINGS, INC.
Duration : Period :
Harmony Biosciences Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HARMONY BIOSCIENCES HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 33,74 $
Average target price 57,00 $
Spread / Average Target 68,9%
EPS Revisions
Managers and Directors
John C.s Jacobs President, Chief Executive Officer & Director
Sandipkumar S. Kapadia Chief Financial Officer
Jeffrey S. Aronin Non-Executive Chairman
Jeffrey M. Dayno Chief Medical Officer
David Bradshaw Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
HARMONY BIOSCIENCES HOLDINGS, INC.-20.87%1 973
JOHNSON & JOHNSON-3.62%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-12.00%220 356